"Previous meetings resulted in a number of collaborations that continue to provide vital progress for Cellmid's therapeutic programs including the recently completed clinical studies carried out at Sahlgrenska Academy, University of Gothenburg, Sweden, demonstrating that midkine is associated with prostate cancer progression and treatment resistance."
